 | |
| Clinical data | |
|---|---|
| Trade names | Leqselvi |
| Other names | CTP-543 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a624047 |
| License data | |
| Routes of administration | By mouth |
| Drug class | Janus kinase inhibitor |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C17H10D8N6 |
| Molar mass | 314.417 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Deuruxolitinib, sold under the brand nameLeqselvi, is a medication used for the treatment ofalopecia areata.[1] It is aJanus kinase inhibitor selective forJAK1 andJAK2.[2] Although the relative effectiveness of deuruxolitinib and another Janus kinase inhibitor—baricitinib—for alopecia areata may vary depending on the population studied, both drugs are more effective than alternative treatments.[3]
Deuruxolitinib was approved for medical use in the United States in July 2024.[4][5][6]
Deuruxolitinib isindicated for the treatment of adults with severe alopecia areata.[1]
The FDA prescribing label for deuruxolitinib contains aboxed warning for serious infections; malignancies; cardiovascular death, myocardial infarction, and stroke; and thrombosis.[1]
Deuruxolitinib was approved for medical use in the United States in July 2024.[4][5][7]
Deuruxolitinib is theinternational nonproprietary name[8] and theUnited States Adopted Name.[9]
